Anika Therapeutics, Inc. (ANIK) Financial Statements
Anika Therapeutics, Inc. (ANIK) reported trailing twelve-month revenue of $120.7M (up 5.3% year on year) and net income of -$3.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $562000.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANIKAnika Therapeutics, Inc.Follow ANIK — free
—
Price chart with a free account
- Market cap
- 286.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.8 | 71.4 | 75.1 | 105.6 | 93.0 | 103.4 | 113.4 | 105.6 | 114.6 | 130.5 | 147.8 | 113.8 | 120.8 | 119.9 | 112.8 | 120.7 | |
| Gross profit | 38.0 | 42.4 | 52.3 | 84.7 | 71.9 | 79.4 | 86.1 | 74.3 | 85.9 | 69.0 | 82.9 | 73.2 | 82.5 | 76.0 | 63.8 | 75.0 | |
| Research & development | 6.2 | 5.4 | 7.1 | 8.1 | 9.0 | 10.7 | 18.8 | 18.2 | 16.7 | 23.4 | 27.3 | 18.3 | 21.8 | 25.5 | 25.8 | 27.5 | |
| Operating income | 14.0 | 19.7 | 32.6 | 61.4 | 48.1 | 50.6 | 45.7 | 21.7 | 34.2 | -28.3 | 2.6 | 3.7 | 0.8 | -5.1 | -11.1 | -5.1 | |
| Pre-tax income | 13.8 | 19.5 | 32.5 | 61.5 | 48.3 | 50.9 | 46.2 | 23.2 | 36.1 | -28.6 | 2.4 | 4.3 | 3.2 | -2.8 | -9.3 | -2.9 | |
| Income tax | 5.3 | 7.8 | 11.9 | 23.2 | 17.5 | 18.3 | 14.4 | 4.5 | 8.9 | -4.6 | -1.7 | 2.1 | 6.6 | 6.1 | 0.7 | 0.2 | |
| Net income | 8.5 | 11.8 | 20.6 | 38.3 | 30.8 | 32.5 | 31.8 | 18.7 | 27.2 | -24.0 | 4.1 | -14.9 | -82.7 | -56.4 | -10.9 | -3.8 | |
| Diluted EPS ($) | 0.62 | 0.82 | 1.39 | 2.51 | 2.01 | 2.15 | 2.11 | 1.27 | 1.89 | -1.69 | 0.28 | -1.02 | -5.64 | -3.83 | -0.76 | -0.27 | |
| Diluted shares (mn) | 13.7 | 14.3 | 14.8 | 15.3 | 15.3 | 15.1 | 15.1 | 14.7 | 14.4 | 14.2 | 14.6 | 14.8 | 14.7 | 14.7 | 14.3 | — |
USD millions · SEC XBRL
Anika Therapeutics, Inc. — questions
- What is Anika Therapeutics, Inc.'s revenue?
- $120.7M over the twelve months to 2026-06-30, up 5.3% year on year, from its 10-Q and 10-K filings.
- What is Anika Therapeutics, Inc.'s net income?
- -$3.8M over the twelve months to 2026-06-30.
- What is Anika Therapeutics, Inc.'s free cash flow?
- $562000 over the twelve months to 2026-06-30.
- What are Anika Therapeutics, Inc.'s diluted earnings per share?
- $-0.27 over the twelve months to 2026-06-30.
Every figure on this page comes from Anika Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.